Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&amp;lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trials

Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Hideto Kameda(Toho University), Hubert van Hoogstraten(Sanofi (United States)), Toshiya Takahashi(Tohoku University), Naoto Kato(Jichi Medical University)
Modern Rheumatology
July 28, 2024
10.1093/mr/roae057
Cited by 4

Related Papers

Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
|The Lancet|2023|164
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
|Arthritis & Rheumatology|2022|151